Pipeline 3.png

ProNOx1, our Multi-site, randomised controlled, blindly evaluated study is now closed and being prepared for submission to a high impact publication.

A phase I dose finding study in Ventilator Associated Pneumonia (NOVAP) has demonstrated the safety and effective delivery of NO by the NO system. A phase III study in Venous Leg Ulcers (VLUs), a randomised controlled transdermal drug delivery study (InNOvate) and a phase I study in microcirculation in septic shock (ProNOx4) are all REC approved and waiting to start.